Conference Details - Overview
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Molecular Oncology: The Sixth Vital Sign, What Every Oncologist Should Know
Arizona Grand Resort
Phoenix, AZ
January 22-24, 2009
Conference Overview
Oncology CME-Certified Conference
Presented by Physicians’ Education Resource in conjunction with the Virginia G. Piper Cancer Center at Scottsdale Healthcare.
Molecular Oncology: The Sixth Vital Sign, What Every Oncologist Should Know is a conference designed to explore the link between the mechanisms of action of novel therapeutics and specific tumor genetic and host clinical features, thereby unifying molecular diagnostics and therapeutics. Given the explosion of new information on the genetic and cellular features of malignancy and the rapidly growing armamentarium of targeted therapeutics, the modern oncologist must master the significance and application of cancer-related basic and clinical sciences. This gap in knowledge and its application in clinical practice will be addressed in this conference.
The goal of this conference is to address the emerging concept of personalized cancer diagnostics and therapeutics, with an emphasis on drug discovery and applications in defined populations. An additional goal is to discuss the application of currently available diagnostic and treatment modalities in a biologically relevant fashion in order to maximize benefit and minimize harm, a process referred to as the sixth vital sign.
Teaching methods utilized in this conference include didactic presentations to create awareness and increase knowledge, case presentations to aid in the integration of information into practice through the use of realistic patient scenarios, and audience polling and discussion to provide opportunities for interaction. Question-and-answer sessions will give the participants the opportunity to reflect on their practice patterns and discuss barriers to implementation with their peers.
This educational program is directed toward oncologists and other care providers who are directly involved in the diagnosis and treatment of malignancies in general oncology and developmental therapeutics. Physicians and other health professionals involved in the care of patients with cancer and researchers who are interested in developing new cancer diagnostics and therapeutics are also invited to attend. At the conclusion of this conference, you should be able to:- Explain molecular and cellular features of malignancy important to diagnostic and therapeutic approaches in cancer and identify novel diagnostic tools that aid in determining these features
- Assess the mechanisms of action and early clinical results of novel targeted therapies for solid tumors and hematologic malignancies
- Identify novel targeted therapies that optimize efficacy and minimize side effects based on specific biologic and clinical scenarios
- Evaluate clinical trial and translational methodologies and their proper use in clinical decision making and patient management
Educational Grants
An educational grant for this activity was provided by:
- Genentech BioOncology
- Merck Oncology
- Celgene Corporation
- Nektar Therapeutics
- Proacta
- Threshold Pharmaceuticals, Inc.
- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company